Brief: Galectin Therapeutics Reports The Positive Outcome Of The Second Data And Safety Monitoring Board Meeting For Navigate, Its Seamless, Adaptive Phase 2B/3 Study Of Belapectin In Patients With Liver Cirrhosis Caused By Non-Alcoholic Steatohepatitis
06/10/2022 13:17
Oct 6 (Reuters) - Galectin Therapeutics Inc GALT.O :
* GALECTIN THERAPEUTICS REPORTS THE POSITIVE OUTCOME OF THE
SECOND
DATA AND SAFETY MONITORING BOARD MEETING FOR NAVIGATE, ITS
SEAMLESS, ADAPTIVE PHASE 2B/3 STUDY OF BELAPECTIN IN PATIENTS
WITH LIVER CIRRHOSIS CAUSED BY NON-ALCOHOLIC STEATOHEPATITIS
* GALECTIN THERAPEUTICS INC- BASED ON ITS DELIBERATION, THE
DSMB
CONCLUDED THAT NAVIGATE CAN CONTINUE AS DESIGNED, WITHOUT
MODIFICATIONS
* GALECTIN THERAPEUTICS INC - BELAPECTIN CONTINUES TO APPEAR
SAFE
AND WELL TOLERATED TO DATE
Further company coverage: GALT.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Galectin Therapeutics
See all newsGalectin Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Galectin Therapeutics Reports June 30, 2026 Financial Results
Galectin Therapeutics Q2 loss widens
Galectin Therapeutics Inc expected to post a loss of 9 cents a share - Earnings Preview
Galectin Therapeutics rises as FDA clears path for late-stage liver drug study